A071702
Trial Overview
Official Title
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Study Purpose
To determine whether the combination of ipilimumab and nivolumab increases the tumor response rate in patients with hypermutated recurrent glioblastoma
Diagnosis
Glioblastoma IDH-wildtype CNS WHO grade 4 Astrocytoma, IDH-mutant CNS WHO grade 4Eligibility
First or second recurrence, must have measurable disease, no requirement of steroid to manage symptoms, certain previous treatment may make the patient ineligible to participate
Intervention
Ipilimumab and Nivolumab given for 4 cycles followed by single agent nivolumab. Treatment continues for as long as the patient is tolerating the drugs and the cancer is controlled
For more information, visit Clinicaltrials.gov
Key Participation Requirements
Trial Location(s)
Gender
Male or Female
Age
19 years and over
Enrollment Status
Suspended
Phase
Phase II
Methodist Health System Trial Code
A071702